Beam Therapeutics Inc. (BEAM) Prices 16.15M Share Offering at $28.48/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy
March 10, 2025 12:59 PM EDTJones Trading analyst Soumit Roy upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Hold to Buy with a price target of $34.00.
The analyst comments "Model changes: We are raising our POS for AATD to 35% from 15%, increasing our adjusted peak sales to ~$1.9BN in 2036, upgrading our rating to Buy from Hold and a PT of $34. BEAM's in vivo edited AATD data mark an important step for the gene editing space, where effective editing levels were observed. Liver biopsy data in the future would accurately quantify the percent editing, but management mentioned that likely >50%... More
